Cancer Nanotechnology最新文献

{"title":"Enhanced chemotherapy response in hepatocellular carcinoma: synergistic effects of miR-122 and doxorubicin co-delivery system inducing apoptosis and DNA damage","authors":"Xiuyun Lin, Jie Liu, Guangfeng Wu, Xiu Yang, Wenqiang Yan, Nanfeng Fan, Hui Li","doi":"10.1186/s12645-024-00287-x","DOIUrl":"https://doi.org/10.1186/s12645-024-00287-x","url":null,"abstract":"Cancer cells can resist chemotherapy through various mechanisms, diminishing treatment outcomes. Research had indicated that combining miR-122 with doxorubicin (DOX) can improve hepatocellular carcinoma (HCC) therapy. To explore this, we created a one-pot co-delivery system, Fe-miR-122/DOX, by coordinating miR-122, DOX, and FeII ions into nanoparticles. These nanoparticles display uniform particle sizes, well-defined morphology, and exceptional colloidal stability in 10% FBS and 20% FBS solution over 24 h. When the ratio of DOX to miR-122 was set at 20:1, the loading efficiency of both drugs reached 54.7% and 55.5%, respectively. Cell experiments confirmed that Fe-miR-122/DOX efficiently delivers both miR-122 and DOX, enabling cytoplasmic delivery through lysosomal escape, facilitated by the positive charge of the nanoparticles. Functionally, miR-122 increases intracellular accumulation of DOX by downregulating P-glycoprotein (P-gp) expression, and it promotes apoptosis by downregulating B-cell lymphoma 2 (Bcl-2), which leads to the upregulation of Caspase-3. Additionally, Fe-miR-122/DOX disrupts cIAPs-mediated anti-apoptotic signals, downregulates PARP-1 expression, hinders DNA repair, promotes DNA fragmentation, enhances caspase-3 expression, and triggers programmed cell death, synergistically enhancing its antitumor efficacy. This synergistic mechanism disrupts DNA repair, amplifying DNA damage and apoptosis. Our cytotoxicity and apoptosis assays (with a HepG2 cell apoptosis rate of 85.98%) demonstrated the potent antitumor capability of Fe-miR-122/DOX. This innovative system has demonstrated good biocompatibility and has the potential to transform HCC therapy. Future research could focus on optimizing the co-delivery system and assessing its efficacy in clinical trials.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"36 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)","authors":"Soheila Montazersaheb, Aziz Eftekhari, Amir Shafaroodi, Soodeh Tavakoli, Sara Jafari, Ayşe Baran, Mehmet Fırat Baran, Sevda Jafari, Elham Ahmadian","doi":"10.1186/s12645-024-00285-z","DOIUrl":"https://doi.org/10.1186/s12645-024-00285-z","url":null,"abstract":"Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Radiation therapy (RT) is a modality for TNBC management. Radiosensitizers can mitigate the adverse effects of RT. Applying green-synthesized silver nanoparticles (Ag-NPs) from biological sources such as plants is a potential strategy to sensitize cancer cells to radiotherapy due to the low toxicity. Therefore, identifying novel natural sources for synthesizing stable and broadly applicable green-Ag-NPs has gained more attention in cancer therapy. In the present study, we synthesized green- Ag-NPs from pumpkin peel extract and elucidated the impact of green-synthesized Ag-NPs as a radiosensitizer in MDA-MB 231 cells (a model of TNBC). The prepared Ag-NPs had a spherical shape with an average size of 81 nm and a zeta potential of − 9.96 mV. Combination of green-synthesized Ag-NPs with RT exhibited synergistic anticancer effects with an optimum combination index (CI) of 0.49 in MDA-MB-231 cells. Green-synthesized Ag-NPs synergistically potentiated RT-induced apoptosis in MDA-MB-231 cells compared to the corresponding monotherapies. Morphological features of apoptosis were further confirmed by the DAPI–TUNEL staining assay. HIF-1α expression was decreased in cells subjected to combination therapy. Bax and p53 expression increased, whereas Bcl-2 genes decreased. Combination therapy significantly increased the protein level of PERK and CHOP while decreasing cyclin D1 and p-ERK/total ERK levels compared to monotherapies. These findings indicate the potential effect of green-synthesized Ag-NPs as a radiosensitizer for TNBC treatment. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"150 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximizing oxaliplatin's impact on EGFR + colorectal cancer through targeted extracellular vesicles","authors":"Shang-Tao Chien, Yi-Jung Huang, Ming-Yii Huang, Yi-Ping Fang, Shi-Wei Chao, Chia-Tse Li, Wun-Ya Jhang, Yun-Han Hsu, Shuo-Hung Wang, Chih-Hung Chuang","doi":"10.1186/s12645-024-00284-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00284-0","url":null,"abstract":"To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to epidermal growth factor receptor (EGFR+) colorectal cancer cells and increase oxaliplatin’s cytotoxicity. Oxaliplatin was passively loaded into a stable cell line expressing cetuximab in membranes. EVs were collected and characterized for size, and their ability to target EGFR+ cells was tested. Cytotoxicity experiments were performed, and a xenograft cancer animal model was used to confirm the specific accumulation of oxaliplatin-loaded EVs with cetuximab-expressing membranes in EGFR+ cells. EVs with cetuximab-expressing membranes were successfully produced and used to encapsulate oxaliplatin, resulting in consistently sized oxaliplatin-loaded EVs with cetuximab-expressing membranes. The oxaliplatin-loaded EVs with cetuximab-expressing membranes were specifically accumulated by EGFR+ cells, leading to significant cytotoxic effects on these cells. In the animal model, the oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin’s therapeutic efficacy against EGFR+ cancer cells. EVs with membrane-expressed bioactive molecules are a promising strategy for delivering therapeutic agents to EGFR+ colorectal cancer cells. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"5 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-frequency ultrasound-assisted drug delivery of chia, cress, and flax conjugated hematite iron oxide nanoparticle for sono-photodynamic lung cancer treatment in vitro and in vivo","authors":"Samir Ali Abd El-Kaream, Doha Farhat Mohamed Zedan, Hagar Mohamed Mohamed, Amal Saleh Mohamed Soliman, Sohier Mahmoud El-Kholey, Mohammed Kamal El-Dein Nasra","doi":"10.1186/s12645-024-00282-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00282-2","url":null,"abstract":"Sono-photodynamic therapy (SPDT), which combines photodynamic (PDT) and sonodynamic (SDT) therapies with sensitizers, offers new avenues for cancer treatment. Even though new sensitizers for SPDT have been synthesized with great success, few of them are effectively used. The limited tumor-targeting specificity, inability to transport the sensitizers deeply intratumorally, and the deteriorating tumor microenvironment limit their anti-tumor effectiveness. The current study was carried out aiming at high-frequency ultrasound-assisted drug delivery of chia, cress and flax conjugated hematite iron oxide nanoparticles (CCF–HIONP) for photothermal–photodynamic lung cancer (LCA) treatment in vitro and in vivo as activated cancer treatment up-to-date modality. The study was conducted in vitro on human LCA cells (A-549) and the study protocol application groups in vivo on Swiss albino mice treated with benzo[a]pyrene only and were not received any treatment for inducing LCA, and only after LCA induction the study treatment protocol began, treatment was daily with CCF–HIONP as HIFU–SPDT sensitizer with or without exposure to laser (IRL) or high-frequency ultrasound (HIFU–US) or a combination of laser and/or high-frequency ultrasound for 3 min for 2 weeks. Revealed that HIONP can be employed as effective CCF delivery system that directly targets LCA cells. In addition, CCF–HIONP is a promising HIFU–SPS for HIFU–SPDT and when combined with HIFU–SPDT can be very effective in treatment of LCA–A549 in vitro (cell viability decreased in a dose-dependent basis, the cell cycle progression in G0/G1 was slowed down, and cell death was induced as evidenced by an increase in the population of Pre-G cells, an increase in early and late apoptosis and necrosis, and an increase in autophagic cell death) and benzo[a]pyrene LCA-induce mice in vivo (decreased oxidative stress (MDA), and ameliorated enzymatic and non-enzymatic antioxidants (SOD, GR, GPx, GST, CAT, GSH, and TAC) as well as renal (urea, creatinine) and hepatic (ALT, AST) functions, induced antiproliferative genes (caspase 3,9, p53, Bax, TNFalpha), suppressed antiapoptotic and antiangiogenic genes (Bcl2,VEGF respectively) and effectively reducing the growth of tumors and even leading to cancer cell death. This process could be attributed to photochemical and/or high-frequency sono-chemical activation mechanism HIFU–SPDT. The results indicate that CCF–HIONP has great promise as an innovative, effective delivery system for selective localized treatment of lung cancer that is activated by HIFU–SPDT.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"86 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)","authors":"Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Rofer, Tian-Lu Cheng, Tung-Ho Wu","doi":"10.1186/s12645-024-00280-4","DOIUrl":"https://doi.org/10.1186/s12645-024-00280-4","url":null,"abstract":"<p><b>Correction: Cancer Nanotechnology (2023) 14:78 </b><b>https://doi.org/10.1186/s12645-023-00230-6</b></p><p>In this article, the author name Tung-Ho Wu was incorrectly written as Dung-Ho Wu. The affiliation of the author is given in this correction.</p><p>The original article has been corrected.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan</p><p>Huei-Jen Chen, Yi-An Cheng, Bo-Cheng Huang & Tian-Lu Cheng</p></li><li><p>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Huei-Jen Chen, Yu-Tung Chen, Chia-Ching Li, Shih-Ting Hong & Steve R. Rofer</p></li><li><p>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Bo-Cheng Huang, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Jaw-Yuan Wang & Tian-Lu Cheng</p></li><li><p>Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Tian-Lu Cheng</p></li><li><p>Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Chiao-Yun Chen</p></li><li><p>Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</p><p>Fang-Ming Chen</p></li><li><p>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan</p><p>Steve R. Rofer</p></li><li><p>Department of Cardiovascular Surgeon, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan</p><p>Tung-Ho Wu</p></li><li><p>School of Medicine, I-Shou University, Kaohsiung, Taiwan</p><p>I.-Ju Chen</p></li></ol><span>Authors</span><ol><li><span>Huei-Jen Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yi-An Cheng</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yu-Tung Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chia-Ching Li</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Bo-Cheng Huang</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Shih-Ting Hong</span>View author publications<p>You can also search for this author in <span>P","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"530 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141942364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts","authors":"Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00279-x","DOIUrl":"https://doi.org/10.1186/s12645-024-00279-x","url":null,"abstract":"<p><b>Retraction</b><b>: </b><b>Cancer Nanotechnology (2023) 14:71 </b><b>https://doi.org/10.1186/s12645-023-00220-8</b></p><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:</p><p>Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.</p><p>Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.</p><ul>\u0000<li>\u0000<p>Fig. 8a D1 appears highly similar to Fig. 8b D3.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 8a E1 and E2 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A9 and b D7 appear to overlap with different contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A10, A12 and B10 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B4 and b D4 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B10 and B11 appear to overlap.</p>\u0000</li>\u0000</ul><p>Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).</p><p>The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Kousain Kousar, Faiza Naseer &amp; Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"154 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141867552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation","authors":"Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00278-y","DOIUrl":"https://doi.org/10.1186/s12645-024-00278-y","url":null,"abstract":"<br/><p><b>Retraction Note: Cancer Nanotechnology (2023) 14:65</b> <b>https://doi.org/10.1186/s12645-023-00218-2</b></p><br/><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:</p><ul>\u0000<li>\u0000<p>Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar</p>\u0000</li>\u0000<li>\u0000<p>Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 18 C6 and D6 appear to overlap (with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)</p>\u0000</li>\u0000</ul><p>The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560</p><p>Article CAS Google Scholar </p></li><li><p>Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Faiza Naseer, Kousain Kousar &amp; Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Sch","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"5 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Studies on the thermal sensitivity of lung cancer cells exposed to an alternating magnetic field and magnesium-doped maghemite nanoparticles","authors":"Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski","doi":"10.1186/s12645-024-00276-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00276-0","url":null,"abstract":"Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"1 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer","authors":"Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari","doi":"10.1186/s12645-024-00275-1","DOIUrl":"https://doi.org/10.1186/s12645-024-00275-1","url":null,"abstract":"Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"12 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma","authors":"Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang","doi":"10.1186/s12645-024-00273-3","DOIUrl":"https://doi.org/10.1186/s12645-024-00273-3","url":null,"abstract":"Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"49 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}